Melbourne event April 3rd, page-77

Axel Hoos was interviewed in January and he made a few points very clear about GSK's oncology programme.


There are some things GSK won’t do in oncology R&D, including their own PD-1 program.
“We will not be a leader in PD-1,” he says. “We have no illusions and it makes no sense.” And there’s no IDO, no CD-19 program, also areas where leaders are well advanced in the field.

And the hunt is on for synergistic tech that can be used to help advance these new platform drugs, with an eye to making the cancer operation profitable after gaining the first new approvals.


https://endpts.com/gsks-long-quiet-...se-as-it-mounts-a-breakout-late-stage-effort/